TY - JOUR
T1 - Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant
AU - The Genotype to Phenotype Japan (G2P-Japan) Consortium
AU - Tsujino, Shuhei
AU - Deguchi, Sayaka
AU - Nomai, Tomo
AU - Padilla-Blanco, Miguel
AU - Plianchaisuk, Arnon
AU - Wang, Lei
AU - Begum, MST Monira
AU - Uriu, Keiya
AU - Mizuma, Keita
AU - Nao, Naganori
AU - Kojima, Isshu
AU - Tsubo, Tomoya
AU - Li, Jingshu
AU - Matsumura, Yasufumi
AU - Nagao, Miki
AU - Oda, Yoshitaka
AU - Tsuda, Masumi
AU - Anraku, Yuki
AU - Kita, Shunsuke
AU - Yajima, Hisano
AU - Sasaki-Tabata, Kaori
AU - Guo, Ziyi
AU - Hinay, Alfredo A.
AU - Yoshimatsu, Kumiko
AU - Yamamoto, Yuki
AU - Nagamoto, Tetsuharu
AU - Asakura, Hiroyuki
AU - Nagashima, Mami
AU - Sadamasu, Kenji
AU - Yoshimura, Kazuhisa
AU - Nasser, Hesham
AU - Jonathan, Michael
AU - Putri, Olivia
AU - Kim, Yoonjin
AU - Chen, Luo
AU - Suzuki, Rigel
AU - Tamura, Tomokazu
AU - Maenaka, Katsumi
AU - Irie, Takashi
AU - Matsuno, Keita
AU - Tanaka, Shinya
AU - Ito, Jumpei
AU - Ikeda, Terumasa
AU - Takayama, Kazuo
AU - Zahradnik, Jiri
AU - Hashiguchi, Takao
AU - Fukuhara, Takasuke
AU - Sato, Kei
N1 - Publisher Copyright:
© 2024 The Author(s). Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.
PY - 2024/9
Y1 - 2024/9
N2 - In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo-electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.
AB - In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo-electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.
KW - COVID-19
KW - EG.5.1
KW - ORF9b
KW - Omicron
KW - SARS-CoV-2
KW - pathogenicity
UR - http://www.scopus.com/inward/record.url?scp=85197898410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85197898410&partnerID=8YFLogxK
U2 - 10.1111/1348-0421.13165
DO - 10.1111/1348-0421.13165
M3 - Article
C2 - 38961765
AN - SCOPUS:85197898410
SN - 0385-5600
VL - 68
SP - 305
EP - 330
JO - MICROBIOLOGY and IMMUNOLOGY
JF - MICROBIOLOGY and IMMUNOLOGY
IS - 9
ER -